Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

letter

. 2021 Dec 16;138(24):2589–2592. doi: 10.1182/blood.2021012315

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by The American Society of Hematology

PMC Copyright notice

Figure 1. — Survival and responses in treatment-naïve (TN) and patients with R/R CLL and del17p and/or TP53 mutations (mut) receiving ibrutinib (Ibr) alone or in combination with rituximab (R). (A) PFS and (B) OS of TN patients with CLL and del17p and/or TP53 mutations (n = 27). (C) PFS and OS (D) of TN CLL patients vs patients with R/R CLL and del17p and/or TP53 mutations. (E) Best responses in the TN patients with del17p and/or TP53 mutations. (F) Best responses in further subset analyses based on treatment (ibrutinib monotherapy/Ibr vs ibrutinib plus rituximab/Ibr + R).